Article

European committee recommends approval of glaucoma treatment

The Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve bimatoprost/timolol ophthalmic solution (Ganfort, Allergan) for treatment of glaucoma.

The Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve bimatoprost/timolol ophthalmic solution (Ganfort, Allergan) for treatment of glaucoma.

CHMP’s opinion is the basis for the European Commission approval. Allergan expects final approval in the second quarter of 2006.

The combination drug’s indication is for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, plus insufficient responsiveness to topical beta-blockers or prostaglandin analogues.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI Myopia Workshop: Michael X. Repka, MD, MBA, on building consensus and future directions
(Image credit: Ophthalmology Times) Introducing iOpeners: Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD
© 2025 MJH Life Sciences

All rights reserved.